7 December 2021 - Late treatment study
US201 Study: A Phase 2, Randomized Proof-of-Concept Trial of Favipiravir for the Treatment of COVID-19
et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofab56310 (Peer Reviewed)
Small very late treatment RCT in the USA, with 25 favipiravir and 25 control patients, showing faster viral clearance with treatment. The benefit was only seen in patients <8 days from symptom onset. There were no significant differences in clinical outcomes. The death in the favipiravir group occurred after discharge and was believed to be unrelated to COVID-19 or favipiravir.
|
risk of death, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 25 (4.0%), control 0 of 25 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
|
|
risk of mechanical ventilation, 200.0% higher, RR 3.00, p = 1.00, treatment 1 of 25 (4.0%), control 0 of 25 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
|
|
hospitalization time, 19.8% higher, relative time 1.20, treatment 25, control 25.
|
|
risk of no recovery, 58.1% lower, RR 0.42, p = 0.08, treatment 25, control 25, day 8 mid-recovery, 6-point ordinal scale, RR approximated with OR.
|
|
risk of no recovery, 46.2% higher, RR 1.46, p = 0.54, treatment 25, control 25, day 15, 6-point ordinal scale, RR approximated with OR.
|
|
recovery time, 42.9% lower, relative time 0.57, treatment 25, control 25, median time to aggregate NEWS2 score ≤2 or discharge.
|
|
recovery time, 15.4% higher, relative time 1.15, treatment 25, control 25.
|
|
time to viral-, 46.7% lower, relative time 0.53, p = 0.04, treatment 25, control 25.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Finberg et al., 12/7/2021, Randomized Controlled Trial, USA, North America, peer-reviewed, 10 authors, average treatment delay 8.4 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.